ALKS 7290 Shows Promising Early Results for Adult ADHD Treatment

Rapid Symptom Relief in Both Inattentive and Hyperactive Domains

A Phase 1b study released this week found that ALKS 7290, an investigational orexin‑2 agonist, markedly reduced symptoms of attention‑deficit/hyperactivity disorder in adults. The double‑blind, placebo‑controlled trial enrolled 80 participants across three U. S. centers and evaluated the drug over a 14‑day period.

The study began in early March and concluded in late April. Participants received either 20 mg or 50 mg of ALKS 7290 daily, with a placebo group for comparison. Researchers measured symptom changes using the Adult ADHD Investigator Symptom Rating Scale (AISRS) and the Clinical Global Impression‑Severity (CGI‑S) scale. Baseline AISRS scores averaged 39, indicating moderate to severe symptoms.

By day 14, the 20‑mg dose lowered AISRS total scores by a median of 14 points, while the 50‑mg dose achieved a 19‑point reduction. These improvements were seen across both inattentive and hyperactive/impulsive subscales, suggesting the drug targets core ADHD features. CGI‑S ratings also improved, with a higher proportion of participants moving from „moderate” to „mild” severity.

Safety Profile Mirrors Existing ADHD Medications

The investigators noted that the drug’s mechanism—stimulating orexin‑2 receptors—may enhance wakefulness and executive function. „The rapid onset of effect is encouraging,” said Dr. Elena Martinez, lead author. „It points to a novel pharmacologic pathway that could complement existing stimulant therapies.”

Adverse events were mild and comparable to placebo. The most common side effects were headache, nausea, and insomnia, each occurring in less than 10% of participants. No serious adverse events were reported, and all participants completed the 14‑day course. Pharmacokinetic analysis showed steady plasma concentrations by day 7, supporting the drug’s tolerability.

The safety data align with the known profile of orexin‑2 agonists used in sleep disorders, suggesting a favorable risk–benefit ratio for future larger trials. „We observed no dose‑related toxicity,” added Dr. Martinez. „That gives us confidence to proceed to Phase 2.”

Will ALKS 7290 Become a New Standard for Adult ADHD?

The study’s short duration limits conclusions about long‑term efficacy and safety. However, the magnitude of symptom reduction within two weeks is notable, especially for adults who often struggle with persistent inattentiveness. The next step will be a Phase 2 trial enrolling 200 participants over six months to assess durability of response and optimal dosing.

If subsequent trials confirm these findings, ALKS 7290 could offer an alternative for patients who do not tolerate stimulants or who require non‑stimulant options. The company plans to file for regulatory approval within the next two years, pending Phase 2 outcomes.

Frequently Asked Questions

What makes ALKS 7290 different from current ADHD drugs? ALKS 7290 targets orexin‑2 receptors, a pathway involved in wakefulness and attention, unlike traditional stimulants that act on dopamine and norepinephrine systems.

How quickly can patients expect improvement? In the Phase 1b study, significant symptom reductions were seen within 14 days, indicating a rapid onset of action.

Are there any known serious side effects? No serious adverse events were reported in the 14‑day trial. Common side effects were mild and included headache, nausea, and insomnia.